BAG3 MUTATION ASSOCIATED DILATED CARDIOMYOPATHY

Clinical trials for BAG3 MUTATION ASSOCIATED DILATED CARDIOMYOPATHY explained in plain language.

Never miss a new study

Get alerted when new BAG3 MUTATION ASSOCIATED DILATED CARDIOMYOPATHY trials appear

Sign up with your email to follow new studies for BAG3 MUTATION ASSOCIATED DILATED CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1

First-in-Human gene therapy trial targets inherited heart weakness

Disease control Recruiting now

This early-stage study is testing a new, one-time gene therapy called ALXN2350 for adults with a specific genetic form of heart muscle disease (BAG3 mutation). The main goals are to find a safe dose and see if the treatment helps control the disease. It will involve a small group…

Matched conditions: BAG3 MUTATION ASSOCIATED DILATED CARDIOMYOPATHY

Phase: PHASE1, PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control

Last updated Mar 16, 2026 15:24 UTC

BAG3 MUTATION ASSOCIATED DILATED CARDIOMYOPATHY

Get alerted when new BAG3 MUTATION ASSOCIATED DILATED CARDIOMYOPATHY trials appear

First-in-Human gene therapy trial targets inherited heart weakness